Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer

  • Authors:
    • P Lissoni
    • A Ardizzoia
    • S Barni
    • G Tancini
    • M Muttini
  • View Affiliations

  • Published online on: September 1, 1996     https://doi.org/10.3892/or.3.5.947
  • Pages: 947-949
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Preliminary results showed that IL-2 immunotherapy may be effective in the treatment of recurring advanced ovarian cancer. The pineal neurohormone melatonin (MLT) has been proven to amplify IL-2 efficacy by counteracting macrophage-mediated immunosuppression. On this basis, a pilot phase II study of low-dose IL-2 plus MLT was performed in advanced ovarian cancer patients progressing after at least 3 previous polychemotherapeutic lines. The study included 12 evaluable patients. IL-2 was injected subcutaneously at 3 million IU/day for 6 days/week for 4 weeks, by repealing the cycle after a al-day rest period in nonprogressing patients. MLT was given orally at 40 mg/day. No complete response was seen. A partial response was achieved in 2/12 (16%) patients. A stable disease was obtained in 5 other patients, whereas the remaining 5 patients progressed. The treatment was well tolerated. This preliminary study suggests that immunotherapy with low-dose IL-2 plus MLT may represent a well tolerated and promising therapy of advanced ovarian cancer progressing on standard medical treatments.

Related Articles

Journal Cover

September 1996
Volume 3 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lissoni P, Ardizzoia A, Barni S, Tancini G and Muttini M: Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer. Oncol Rep 3: 947-949, 1996
APA
Lissoni, P., Ardizzoia, A., Barni, S., Tancini, G., & Muttini, M. (1996). Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer. Oncology Reports, 3, 947-949. https://doi.org/10.3892/or.3.5.947
MLA
Lissoni, P., Ardizzoia, A., Barni, S., Tancini, G., Muttini, M."Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer". Oncology Reports 3.5 (1996): 947-949.
Chicago
Lissoni, P., Ardizzoia, A., Barni, S., Tancini, G., Muttini, M."Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer". Oncology Reports 3, no. 5 (1996): 947-949. https://doi.org/10.3892/or.3.5.947